The CLASS Trial: Why This Vein Study is Misleading Doctors and Patients (My Own Personal Opinion)

Foam Sclerotherapy vs Laser Ablation

If you're a vein specialist or healthcare professional interested in treating varicose veins, you might assume published research in a prestigious journal is reliable.

Unfortunately, that's not always the case, and the CLASS TRIAL is a prime example of how misleading research can influence treatment decisions.

The Class Trial Reviewed:

The CLASS trial, a randomised control trial comparing endovenous laser ablation, ultrasound-guided foam sclerotherapy, and surgery for treating primary varicose veins, is often cited at vein meetings, particularly in the UK. However, this study has several flaws that undermine its conclusions and raise concerns about its relevance to modern vein care.

1. Unequal Comparison:

The CLASS trial isn't a true comparison of surgery, laser, and foam sclerotherapy. Patients weren't randomised to all three treatment options at every hospital. Some hospitals only randomised patients to surgery and foam sclerotherapy (stratum 2), while others randomised to all three treatments (stratum 1). This limits the ability to directly compare the effectiveness of all three interventions across all study sites.

2. Foam Sclerotherapy Used in Two Groups:

The abstract suggests that laser, foam sclerotherapy, and surgery were compared, but foam sclerotherapy was administered in two of the treatment groups. This isn't a fair comparison of foam versus laser when laser patients also received foam.

3. Significant Exclusion Rate:

While 798 participants were studied, 5,794 were excluded. This raises concerns about the study's representation of real-world vein patients.

4. Outdated Foam Sclerotherapy Technique:

Perhaps the most critical flaw is the outdated foam sclerotherapy method used. Only one injection site was used for the trunk, and foam was massaged up the full vein length. Current best practice by foam sclerotherapy experts utilises multiple injection sites for better efficacy. The method used in the CLASS trial is considered inadequate by today's standards.

5. Small Sample Size for Key Comparisons:

Despite the seemingly large overall number, only 203 received laser (with foam) and 265 received foam only. These numbers are too small for a robust comparison between these two key treatment options.

Summary Opinion of The Class Trial:

The CLASS trial has significant limitations that impact its validity and relevance to current vein treatment practices. It's time to stop quoting this study and engage in a proper debate about the role of modern foam sclerotherapy. We need to base our treatment decisions on up-to-date research that accurately reflects the techniques used today.

Call to Action:

Let's move beyond the CLASS TRIAL and embrace the full potential of foam sclerotherapy.